(NGEN) NervGen Pharma - Ratings and Ratios

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing innovative treatments for nervous system injuries and diseases. Its lead compound, NVG-291, is a glycine transporter inhibitor currently in Phase 1b/2a clinical trials for spinal cord injuries (SCI), multiple sclerosis, and Alzheimers disease. The drug aims to enhance synaptic plasticity, a key mechanism for nervous system repair. NervGen holds an exclusive licensing agreement with Case Western Reserve University for a patented technology targeting spinal cord injury and other nerve damage-related conditions. The company, established in 2017 and headquartered in Vancouver, Canada, is advancing its pipeline to address significant unmet medical needs in neurology and regenerative medicine.

From a technical perspective, NervGens stock (NGEN) on the TSX Venture Exchange shows a 20-day average volume of 30,586 shares, with a last price of CAD 2.80. The stock is trading slightly below its 20-day (2.89) and 50-day (2.95) moving averages but above its 200-day moving average (2.67), indicating short-term weakness but longer-term strength. The Average True Range (ATR) of 0.10 reflects low volatility. On the fundamental side, the company has a market capitalization of CAD 194.05 million and a price-to-book (P/B) ratio of 21.14, suggesting high valuation relative to book value. With no earnings reported, the P/E ratio is undefined.